Tuberculosis in orthotopic liver transplant patients: Increased toxicity of recommended agents; cure of disseminated infection with nonconventional regimens

Transplantation

Volumn 69, Issue 1, 2000, Pages 64-69

  Meyers, Burt R ^a   Papanicolaou, Genovefa A ^a   Sheiner, Patricia ^a   Emre, Sukru ^a   Miller, Charles ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LIVER BIOPSY; LIVER TOXICITY; LIVER TRANSPLANTATION; MALE; MORTALITY; PRIORITY JOURNAL; TUBERCULOSIS;

EID: 0034650556     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200001150-00013     Document Type: Article

References (37)

1. Tuberculosis morbidity - United States, 1997. MMWR 1998; 47: 2253-57.
2. Meyers Br, Halpern M, Sheiner P, Mendelson MH, Neibart E, Miller C. Tuberculosis in liver transplant patients. Transplantation 1994; 58: 301.
3. Higgins RSD, Cahn AP, Porter D, Richardson AJ, Mitchell RG, Hopkin JM, Moris PJ. Mycobacterial infections after renal transplantation. Q J Med 1991; 78: 145.
4. Lichtenstein IH, MacGregor RR. Mycobacterial infections in renal transplant recipients: report of five cases and review of the literature. Rev Infect Dis 1983; 5: 216.
5. Qunibi WY, al-Sibai MB, Taher S, et al. Mycobacterial infection after renal transplantation - report of 14 cases and review of the literature. Q J Med 1990; 77: 1039-1060.
6. Stoblen F, Neuhaus K, Neumann O, et al. Tuberculosis in Liver Transplant Recipients: Recurrence After Transplantation? Transplant Proc 1994; 26: 3604.
7. Higgins RSD, Kusne S, Reyes J et al. Mycobacterium tuberculosis after liver transplantation: Management and guidelines for prevention. Clin Transplant 1992; 6: 81.
8. Aguado JM, Herrero JA, Gavalda J, et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Transplantation 1997; 63: 1278.
9. Snider DE, Caras GJ. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992; 145: 494.
10. Israel HL, Gottlieb JE, Maddrey WC. Perspective: preventive isoniazid therapy and the liver. Chest 1992; 101: 1298.
11. Mitchell JR, Zimmerman HJ, Ishak KG, et al. Isoniazid liver injury: clinical spectrum, pathology and probable pathogenesis. Ann Intern Med 1976; 84: 181.
12. Antony SJ, Ynares C, Dummer JS. Isoniazid hepatotoxicity in renal transplant recipients. Clin Transplant 1997; 11: 34.
13. Mitchell JR, Jollow DJ. Progress in hepatology. Metabolic activation of drugs to toxic substances. Gastroenterology 1975; 68: 392.
14. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin: a meta-analysis. Chest 1991; 99: 465.
15. Schluger LK, Sheiner PA, Jonas M, et al. Isoniazid hepatotoxicity after orthotopic liver transplantation. Mt Sinai J Med 1996; 63: 364.
16. Ohnhaus EE, Park BK. Measurement of urinary 6-betahydroxy-cortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme inducing capacity of anti-pyrine, phenobarbitone and rifampicin. Eur J Clin Pharmacol 1979; 15: 139.
17. Perry W, Jenkins MV, Setchell KDR, Stamp TCB. Induction and inhibition of hepatic microsomal enzymes by rifampicin and isoniazid (Abstract). Clin Sci Mol Med 1978; 55: 21.
18. Sinnott ST 4th, Emmanuel PJ. Mycobacterial infections in the transplant patient. Semin Resp Infect 1990; 5: 65.
19. Adler JJ, Meyers Br, Miller C, Klion F. Pyrazinamide (PZA) induced acute hepatic necrosis treated with liver transplant (Abstract). American Lung Association/American Thoracic Society International Conference, San Francisco, CA, May 1993.
20. American Thoracic Society and the Center for Disease Control and Prevention. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149: 1359.
21. Kohno S, Koga H, Kaku M, Maesaki S, Kara K. Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis. Chest 1992; 102: 1815.
22. Tsukamura M. In vitro antituberculosis activity of a new antibacterial substance ofloxacin (DL8280). Am Rev Respir Dis 1985; 131: 348.
23. Tsukamura M, Nakamura E, Yoshii S, Amano H. Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. Am Rev Respir Dis 1985; 131: 352.
24. Yew WW, Kwan SY, MA WK, Hin MA, Chan PY. In-vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis. J Antimicrob Chemother 1990; 26: 227.
25. Crowle AJ, Elkins N, May MH. Effectiveness of ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium and rifampin against Mycobacterium tuberculosis in human macrophages. Am Rev Respir Dis 1990; 137: 1141.
26. Kennedy N, Fox R, Kisyombe GM, Saruni AO, Uiso LO, Ramsay AR, Ngowi FI, Gillespie SH. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. Am Rev Respir Dis 1993; 148: 1547.
27. Kennedy N, Berger L, Curran J et al. Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clin Infect Dis 1996; 22: 827.
28. Thung SW, Gerber MA. Acute hepatitis versus celluluar liver allograft rejection. In: Thung SN, Berger MA, eds. Differential diagnosis in pathology: liver disorders. New York: Igaku-Shoin, 1995: 920.
29. Offermann G, Keller F, Molzahn M. Low cyclosporine A blood level and acute graft rejection in a renal transplant recipient during rifampin treatment. Am J Nephrol 1985; 5: 385.
30. Modry DL, Stinson EB, Oyer PE et al. Acute rejection and massive cyclosporine requirements in heart transplant recipients treated with rifampin. Transplantation 1985; 39: 313.
31. Salomon N, Perlman DC, Goldstein S. Special problems in treating tuberculosis, (letter) Ann Intern Med 1994; 120: 440.
32. Combs DL, O'Brien RJ, Geiter LJ. USPHS tuberculosis short-course therapy trial 21: effectiveness, toxicity and acceptability. The report of final results. Ann Intern Med 1990; 112-397.
33. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear negative pulmonary tuberculosis. Results at 5 years. Am Rev Respir Dis 1989; 139: 871.
34. Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. Ann Intern Med 1990; 112: 407.
35. Dutt AK, Moers D, Stead WW. Smear- and culture-negative pulmonary tuberculosis: four-month short course chemotherapy. Am Rev Respir Dis 1989; 139: 867.
36. nd study of the short-term treatment administered in Madras. Bull Int Union Tuberc 1983; 58: 97.
37. Mehrotra ML, Gautam KD, Chaube CK. Shortest possible ac-ceptable, effective ambulatory chemotherapy in ambulatory patients with pulmonary tuberculosis. Part II. Results during the 24 months after the end of chemotherapy. Am Rev Respir Dis 1984; 129: 1016.